成人皮肌炎合并钙质沉着症的临床特征、治疗与结局:单队列研究
单中心队列纳入627例成人皮肌炎患者,其中35例(5.6%)合并钙质沉着症。多因素分析显示发病年龄较轻、吞咽困难、皮肤溃疡及抗核基质蛋白2抗体阳性与钙质沉着症独立相关;双膦酸盐治疗未见显著疗效,但总体健康结局良好。
要点
- 成人皮肌炎中钙质沉着症发生率5.6%,发病年龄较轻、吞咽困难、皮肤溃疡及抗NXP2抗体阳性为独立相关因素。
- 双膦酸盐治疗未显示改善钙质沉着症的治疗反应。
- 钙质沉着症组死亡率5.7%,60.6%呈慢性多循环病程,17.1%出现轻度继发并发症。
核心结论
- 钙质沉着症是成人皮肌炎不常见但重要的临床特征,双膦酸盐未显示有效治疗作用,但患者总体健康结局良好。
研究设计与样本
- 单队列研究,初始纳入627例成人皮肌炎患者,其中35例(5.6%)发现钙质沉着症,分析该亚组的临床特征,并采用Poisson回归模型分析相关风险因素。
主要发现
- 多因素分析显示发病年龄较轻(OR=0.945,95%CI 0.925–0.966,P<0.001)、吞咽困难(OR=2.609,95%CI 1.189–5.728,P=0.017)、皮肤溃疡(OR=5.705,95%CI 3.041–10.705,P<0.001)及抗核基质蛋白2抗体阳性(OR=5.917,95%CI 2.754–12.714,P<0.001)与钙质沉着症独立相关。
- 在低剂量和高剂量泼尼松治疗组中,接受双膦酸盐治疗与未接受双膦酸盐治疗的患者治疗反应均无差异(P=1.000和P=0.375)。
- 随访显示钙质沉着症组死亡率为5.7%,60.6%的病例呈慢性多循环病程,17.1%出现钙质沉着症继发的轻度并发症。
关键数值与推荐
- 钙质沉着症在成人皮肌炎患者中的发生率为5.6%(35/627)。
- 与钙质沉着症独立相关的因素:发病年龄较轻(OR=0.945,95%CI 0.925–0.966,P<0.001)、吞咽困难(OR=2.609,95%CI 1.189–5.728,P=0.017)、皮肤溃疡(OR=5.705,95%CI 3.041–10.705,P<0.001)、抗核基质蛋白2抗体阳性(OR=5.917,95%CI 2.754–12.714,P<0.001)。
- 双膦酸盐治疗与未治疗组在低剂量泼尼松组(P=1.000)和高剂量泼尼松组(P=0.375)中治疗反应均无差异。
- 钙质沉着症组死亡率为5.7%,60.6%呈慢性多循环病程,17.1%有轻度继发并发症。
临床怎么用
- 对成人皮肌炎患者应关注钙质沉着症的发生,尤其是发病年龄较轻、伴吞咽困难、皮肤溃疡或抗NXP2抗体阳性者。
- 双膦酸盐未显示有效治疗钙质沉着症,临床决策需综合评估,不宜仅基于此证据常规推荐。
- 钙质沉着症患者总体健康结局良好,但需注意慢性多循环病程及继发并发症的长期管理。
局限性
- 单中心队列研究,钙质沉着症亚组样本量较小(35例),结论外推需谨慎。
- 原文未报告研究的具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The occurrence of calcinosis cutis as a clinical feature of dermatomyositis in adult patients is not well understood. Cohort studies of adult patients with calcinosis are rare. We systematically describe the clinical features, treatments and outcomes of adult patients with calcinosis. METHODS: We initially enrolled 627 adult DM patients. Of those enrolled, 35 (5.6%) were found to have calcinosis. We analysed the clinical features associated with calcinosis in this subgroup. The risk factors associated with calcinosis were analysed using the Poisson regression model. RESULTS: Multivariate analysis showed that a younger age at disease onset [odds ratio (OR) = 0.945, 95% CI 0.925, 0.966, P < 0.001], dysphagia (OR = 2.609, 95% CI 1.189, 5.728, P = 0.017), skin ulcer (OR = 5.705, 95% CI 3.041, 10.705, P < 0.001) and the presence of anti-nuclear matrix protein 2 antibody (OR = 5.917, 95% CI 2.754, 12.714, P < 0.001) were independently associated with calcinosis. In both the low- and high-dose prednisone treatment groups, no difference in treatment response was seen between the bisphosphonate treatment group and the group not receiving bisphosphonate treatment (P = 1.000 and P = 0.375, respectively). A follow-up study revealed that the mortality rate of the calcinosis group was 5.7%. Additionally, 60.6% of the cases had a chronic polycyclic disease course and 17.1% had mild complications secondary to calcinosis. CONCLUSION: Calcinosis is an uncommon, but significant clinical feature in adult patients with DM. Bisphosphonates were not found to effectively treat calcinosis, however, the overall health outcomes of adult DM patients with calcinosis were favourable.
引用
- Jiang W, Yang H, Li S, et al. Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study. Rheumatology (Oxford). 2021. PMID: 33249499. doi:10.1093/rheumatology/keaa618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。